M. Fagura

发表

Use of a Canine Model of Atopic Dermatitis to Investigate the Efficacy of a CCR4 Antagonist in Allergen-Induced Skin Inflammation in a Randomized Study.

I. Peers, R. Marsella, J. Reens, 2016, The Journal of investigative dermatology.

Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists.

Martin Braddock, Keith Bowers, Richard Weaver, 2003, Bioorganic & medicinal chemistry letters.

Discovery of pyrazoles as novel FPR1 antagonists.

M. Wenlock, J. Unitt, Bryan E. Roberts, 2011, Bioorganic & medicinal chemistry letters.

Human stem cell osteoblastogenesis mediated by novel glycogen synthase kinase 3 inhibitors induces bone formation and a unique bone turnover biomarker profile in rats.

P. Hall, P. Gilmour, J. Pilling, 2013, Toxicology and applied pharmacology.

Novel P2X7 receptor antagonists.

M. Braddock, A. Baxter, M. Robertson, 2003, Bioorganic & medicinal chemistry letters.

Expression and functions of purinergic receptor P2X7 in colonic macrophages and T lymphocytes from normal and inflammatory bowel disease mucosa

T. Gray, C. Hawkey, C. Li, 2001 .

Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors.

Martin Braddock, Mark Furber, Keith Bowers, 2007, Journal of medicinal chemistry.

Characterization of a selective and potent antagonist of human P2X7 receptors, AZ11645373

M. Braddock, A. Surprenant, L. Stokes, 2006, British journal of pharmacology.

Human stem cell osteoblastogenesis mediated by novel glycogen synthase kinase 3 inhibitors induces bone formation and a unique bone turnover biomarker profile in rats.

K. J. Escott, J. Pilling, H. Sanganee, 2013, Toxicology and applied pharmacology.

Discovery of small molecule human FPR1 receptor antagonists.

J. Unitt, R. Weaver, A. Baxter, 2009, Bioorganic & medicinal chemistry letters.